This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Extensive study has been performed on compounds of the form M4AnO2(CO3)3, where M represents a monovalent cation and An is either uranium, neptunium, or plutonium. Since 1967, when neptunium(VII) was discovered, some coordination compounds with neptunium in the +7 oxidation state have been prepared and studied. The first reported such compound was initially characterized as Co(NH3)6NpO5·nH2O in 1968, but was suggested in 1973 to actually have the formula [Co(NH3)6][NpO4(OH)2]·2H2O based on the fact that Np(VII) occurs as [NpO4(OH)2]3− in aqueous solution. This compound forms dark green prismatic crystals with maximum edge length 0.15–0.4 mm.
== Efficacy == Being a dual PPAR agonist, saroglitazar helps in controlling blood glucose and lipid parameters, especially high triglycerides and high non-HDL cholesterol. A study done in rats concluded that saroglitazar has the potential to prevent the progression of retinopathy in diabetes patients. Using preclinical models, it has also been shown to be useful in diabetic nephropathy.
== Georgian military interviews == According to Georgian military interviewed by EurasiaNet, they believed their action initially intended to restore security for Georgian villages in South Ossetia, with one lieutenant from 4th Brigade saying: "Our goal was to put an end to fighting in the area and take control. Nobody in the army expected a war with Russia." Georgian soldiers said they had earlier anticipated an attack from Abkhazia, with the 4th Brigade lieutenant saying that they "were preparing for something in May when Georgia was denied NATO membership [a Membership Action Plan]." There "were no preparations made" for a military action in South Ossetia in August, since "Many were on vacation and we were preparing to go Iraq in the fall." The 4th brigade loaded tanks and missile launchers on a train, destined for the city of Gori, after receiving an unexpected alarm call on 7 August 2008. The 4th Brigade began an operation against South Ossetian separatists during the night of 7–8 August, which marked their first combat, and undertook action in three directions, one of which was intended to deflect South Ossetians from the main Georgian goal. One anonymous mid-ranking commander said Georgian army attempted to take control over an important road to the north of Tskhinvali (leading to the Roki Tunnel), which was being defended by South Ossetian garrison near the village of Tbeti and the first Russian tanks arrived during this battle. The anonymous Georgian commander also said, "We destroyed one tank after another, but they kept coming."
=== Adaptive immunity === Activated platelets are able to participate in adaptive immunity, interacting with antibodies. They are able to specifically bind IgG through FcγRIIA, a receptor for IgG's constant fragment (Fc). When activated and bound to IgG-opsonised bacteria, platelets release reactive oxygen species (ROS), antimicrobial peptides, defensins, kinocidins and proteases, killing the bacteria directly. Platelets also secrete proinflammatory and procoagulant mediators such as inorganic polyphosphates or platelet factor 4 (PF4), connecting innate and adaptive immune responses.
urged Ukrainians to remain within the Soviet Union, calling the choice between backing Gorbachev and backing independence movements a "false choice" and pledged to maintain "the strongest possible relationship" with Gorbachev's government. Ukrainians ignored him within months, voting overwhelmingly for independence that December—not, per Judt, from any sudden patriotic awakening, but because independence had become a matter of self-preservation rather than self-determination. The episode undercuts the self-congratulatory narrative that later entered the American public record; Washington did not bring communism down inasmuch as it simply watched it implode on its own schedule. In an attempt to halt the rapid changes to the system, a group of Soviet hardliners represented by Vice President Gennady Yanayev launched a coup against Gorbachev in August 1991. Yeltsin's response did more to decide the coup's outcome than any single military calculation: emboldened by a personal meeting with Bush just three weeks earlier, he denounced the takeover as an illegal coup d'état from the Russian parliament building, directed the resistance from its steps, and conducted a running set of negotiations with world leaders before the assembled international press—all but one of whom withheld recognition from the plotters.
Sources: en.wikipedia.org
The presidential transition period began following Trump's victory in the 2024 U.S. presidential election, though Trump had chosen Linda McMahon and Howard Lutnick to begin planning for the transition in August 2024. According to The New York Times, Trump was "superstitious" and preferred to avoid discussing the presidential transition process until after Election Day. His transition team relied on the work of the America First Policy Institute, rather than the Heritage Foundation, a conservative think tank that garnered controversy during the election for Project 2025, a set of initiatives that would reshape the federal government. By October, he had not participated in the federal presidential transition process, and he had not signed a required ethics pledge, as of November. During the transition period, Trump announced nominations for his cabinet and administration. Trump was inaugurated on January 20, 2025. He was sworn in by Chief Justice John Roberts. The inauguration occurred indoors in the Capitol Rotunda as a result of a severe cold wave.
== Function == Epiplakin's role in maintaining keratin intermediate filament organization suggests that dysregulation of epiplakin expression or function may contribute to epithelial fragility or altered wound-healing responses, as indicated by accelerated wound closure observed in epiplakin-depleted corneal epithelial cells.
== Diagnostics == Optimer diagnostics are being developed across a number of platforms, such as biosensors, LFD and ELISA, for point-of-care diagnostics. Current partnerships include the development of COVID-19 LFD and breath test rapid antigen tests, biosensor tests for wastewater contaminants, biosensor tests for chemotherapeutic drug monitoring and biomarker discovery platforms to support drug discovery.
It was replaced in 1996 with a tan outer bag that was better suited for service in the deserts of the Middle East. By 2000, a bean burrito main dish was introduced. In 2006, "Beverage Bags" were introduced to the MRE, as service members have begun to depend more on hydration packs than on canteens, thus denying them the use of the metal canteen cups (shaped to fit in a canteen pouch with the canteen) for mixing powdered beverages. In addition to having measuring marks to indicate levels of liquid for precise measurement, they can be sealed and placed inside the flameless heater. Most recently, MREs have been developed using the Dietary Reference Intake, created by the Institute of Medicine (IOM). The IOM indicated service members (who were classified as highly active men between the ages of 18 and 30) typically burn about 4,200 Calories (kcal) a day, but tended to only consume about 2,400 Calories a day during combat, entering a negative energy balance. This imbalance occurs when service members fail to consume full portions of their rations. Although manipulations to the food items and distribution of macronutrients to help boost the amount of kilocalories per MRE have been made, more studies are showing many service members still do not meet today's standards of daily consumption, often trading and discarding portions of the ration. Researchers continue to study the habits and eating preferences of service members, making constant changes that encourage service members to eat the entire meal and thus get full nutritional value.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.